DENALI THERAPEUTICS INC's ticker is DNLI and the CUSIP is 24823R105. A total of 216 filers reported holding DENALI THERAPEUTICS INC in Q1 2021. The put-call ratio across all filers is 0.32 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $5,259,433 | -27.3% | 254,941 | +3.9% | 1.02% | -15.2% |
| Q2 2023 | $7,238,537 | +28.3% | 245,291 | +0.2% | 1.21% | +11.3% |
| Q1 2023 | $5,641,344 | -16.8% | 244,850 | +0.4% | 1.08% | -17.4% |
| Q4 2022 | $6,781,469 | -9.2% | 243,850 | +0.2% | 1.31% | -10.8% |
| Q3 2022 | $7,468,000 | +25.6% | 243,350 | +20.4% | 1.47% | +22.8% |
| Q2 2022 | $5,948,000 | -10.7% | 202,100 | -2.4% | 1.20% | +1.3% |
| Q1 2022 | $6,662,000 | -21.2% | 207,100 | +9.2% | 1.18% | -7.1% |
| Q4 2021 | $8,456,000 | +31.5% | 189,600 | +48.7% | 1.27% | +137.9% |
| Q3 2021 | $6,432,000 | +26.1% | 127,500 | +96.2% | 0.54% | +29.5% |
| Q2 2021 | $5,099,000 | +2136.4% | 65,000 | +1525.0% | 0.41% | +2329.4% |
| Q1 2021 | $228,000 | -1.7% | 4,000 | -58.3% | 0.02% | -19.0% |
| Q2 2020 | $232,000 | – | 9,600 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Crestline Management, LP | 19,462,500 | $339,037,000 | 35.95% |
| Euclidean Capital LLC | 323,749 | $27,117,000 | 5.74% |
| Flagship Pioneering Inc. | 2,730,263 | $228,687,000 | 4.16% |
| Casdin Capital, LLC | 1,310,000 | $109,726,000 | 3.25% |
| A.R.T. Advisors, LLC | 6,173 | $517,000 | 2.39% |
| MARK ASSET MANAGEMENT LP | 172,040 | $14,410,000 | 1.73% |
| Temasek Holdings (Private) Ltd | 4,410,457 | $369,420,000 | 1.59% |
| Integral Health Asset Management, LLC | 57,500 | $4,816,000 | 1.43% |
| GILDER GAGNON HOWE & CO LLC | 3,219,843 | $269,694,000 | 1.34% |
| IRONWOOD INVESTMENT MANAGEMENT LLC | 19,365 | $1,622,000 | 0.95% |